FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950559964> ?p ?o ?g. }

• W2950559964 endingPage "4028" @default.
• W2950559964 startingPage "4028" @default.
• W2950559964 abstract "4028 Background: HCC is a vascular tumor with poor prognosis. Although S has been shown to improve survival, its ability to induce tumor shrinkage is very low. Given the activity of Gemcitabine and Oxaliplatin (GEMOX) in HCC, a phase II trial combining S with GEMOX was undertaken to define efficacy and safety profile. Methods: Patients with inoperable advanced and/or metastatic HCC (BCLCC B or C), with or without prior palliative chemoembolization, Child pugh score A, WHO performance status (PS) 0-1, were eligible for this two-stage, randomized phase II trial. Patients received S (400 mg BID) alone (arm A) or in combination with GEMOX every 2 weeks (gem. 1000 mg/m² [10 mg/m²/min] on D1; oxaliplatin, 100 mg/m² on D2) (arm B). Randomization was stratified according to CLIP score (0-1 vs. 2-3) and center. Primary endpoint was crude 4-mo Progression-Free Survival (PFS) rate (H0, < 50%; H1, ≥ 70%; α = 10%; 1- β= 90%). Results: From Dec 2008 to Oct. 2011, 94 pts were enrolled: median age, 64 yrs; male, 88%; PS 0 (69%) 1(31%), CLIP 0-1 (48%) 2-3 (52%), cirrhosis (63%), portal vein thrombosis (29%), extra liver metastasis (69%). These characteristics were well balanced in both arms. Median duration and dose intensity of S were 4 mo (1-27) and 81% in both arms, respectively. Median number of GEMOX cycles was 7 (1-12) in arm B. Main severe (grade 3-4) toxicity (arm A/B) consisted of neutropenia (grade 3-4: 0%/7%), fatigue (18%/24%), thrombocytopenia (0%/9%), diarrhea (grade 2-4: 10%/21%), peripheral neuropathy (grade 2-3: 0%/10%), and hand foot syndrome (grade 2-3: 13%/7%). For evaluable pts (n = 83), ORR was 9% / 16% and DCR was 70%/77% in arms A/B, respectively. For all pts (median follow-up, 17.6 mo), 4-mo PFS rate was 54%/61%, median PFS was 4.6 (3.9-6.2)/6.2 (3.8-6.8) mo, and median OS was 13.0 (10.4-22.2) /13.5 (7.5-19.1) mo in arms A/B, respectively. Conclusions: S plus GEMOX was feasible in HCC. This trial met its primary endpoint (4-mo PFS ≥ 50%) and ORR, median PFS and OS were encouraging data. Exploratory analyses are underway to identify subgroups of patients likely to derive most benefit from this combination. Clinical trial information: NCT00941967." @default.
• W2950559964 created "2019-06-27" @default.
• W2950559964 creator A5005521442 @default.
• W2950559964 creator A5006848714 @default.
• W2950559964 creator A5010459987 @default.
• W2950559964 creator A5014414514 @default.
• W2950559964 creator A5014415808 @default.
• W2950559964 creator A5033590515 @default.
• W2950559964 creator A5039119608 @default.
• W2950559964 creator A5039535296 @default.
• W2950559964 creator A5041492973 @default.
• W2950559964 creator A5052064056 @default.
• W2950559964 creator A5055916060 @default.
• W2950559964 creator A5077000250 @default.
• W2950559964 creator A5082631947 @default.
• W2950559964 creator A5090251954 @default.
• W2950559964 date "2013-05-20" @default.
• W2950559964 modified "2023-10-17" @default.
• W2950559964 title "Sorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial)." @default.
• W2950559964 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.4028" @default.
• W2950559964 hasPublicationYear "2013" @default.
• W2950559964 type Work @default.
• W2950559964 sameAs 2950559964 @default.
• W2950559964 citedByCount "14" @default.
• W2950559964 countsByYear W29505599642013 @default.
• W2950559964 countsByYear W29505599642014 @default.
• W2950559964 countsByYear W29505599642015 @default.
• W2950559964 countsByYear W29505599642016 @default.
• W2950559964 countsByYear W29505599642017 @default.
• W2950559964 countsByYear W29505599642019 @default.
• W2950559964 countsByYear W29505599642020 @default.
• W2950559964 countsByYear W29505599642022 @default.
• W2950559964 crossrefType "journal-article" @default.
• W2950559964 hasAuthorship W2950559964A5005521442 @default.
• W2950559964 hasAuthorship W2950559964A5006848714 @default.
• W2950559964 hasAuthorship W2950559964A5010459987 @default.
• W2950559964 hasAuthorship W2950559964A5014414514 @default.
• W2950559964 hasAuthorship W2950559964A5014415808 @default.
• W2950559964 hasAuthorship W2950559964A5033590515 @default.
• W2950559964 hasAuthorship W2950559964A5039119608 @default.
• W2950559964 hasAuthorship W2950559964A5039535296 @default.
• W2950559964 hasAuthorship W2950559964A5041492973 @default.
• W2950559964 hasAuthorship W2950559964A5052064056 @default.
• W2950559964 hasAuthorship W2950559964A5055916060 @default.
• W2950559964 hasAuthorship W2950559964A5077000250 @default.
• W2950559964 hasAuthorship W2950559964A5082631947 @default.
• W2950559964 hasAuthorship W2950559964A5090251954 @default.
• W2950559964 hasConcept C121608353 @default.
• W2950559964 hasConcept C126322002 @default.
• W2950559964 hasConcept C168563851 @default.
• W2950559964 hasConcept C203092338 @default.
• W2950559964 hasConcept C2777214474 @default.
• W2950559964 hasConcept C2778019345 @default.
• W2950559964 hasConcept C2778695046 @default.
• W2950559964 hasConcept C2780258809 @default.
• W2950559964 hasConcept C2780962732 @default.
• W2950559964 hasConcept C526805850 @default.
• W2950559964 hasConcept C71924100 @default.
• W2950559964 hasConcept C90924648 @default.
• W2950559964 hasConceptScore W2950559964C121608353 @default.
• W2950559964 hasConceptScore W2950559964C126322002 @default.
• W2950559964 hasConceptScore W2950559964C168563851 @default.
• W2950559964 hasConceptScore W2950559964C203092338 @default.
• W2950559964 hasConceptScore W2950559964C2777214474 @default.
• W2950559964 hasConceptScore W2950559964C2778019345 @default.
• W2950559964 hasConceptScore W2950559964C2778695046 @default.
• W2950559964 hasConceptScore W2950559964C2780258809 @default.
• W2950559964 hasConceptScore W2950559964C2780962732 @default.
• W2950559964 hasConceptScore W2950559964C526805850 @default.
• W2950559964 hasConceptScore W2950559964C71924100 @default.
• W2950559964 hasConceptScore W2950559964C90924648 @default.
• W2950559964 hasIssue "15_suppl" @default.
• W2950559964 hasLocation W29505599641 @default.
• W2950559964 hasOpenAccess W2950559964 @default.
• W2950559964 hasPrimaryLocation W29505599641 @default.
• W2950559964 hasRelatedWork W1879835999 @default.
• W2950559964 hasRelatedWork W2021965961 @default.
• W2950559964 hasRelatedWork W2036867087 @default.
• W2950559964 hasRelatedWork W2062847965 @default.
• W2950559964 hasRelatedWork W2099011410 @default.
• W2950559964 hasRelatedWork W2244660108 @default.
• W2950559964 hasRelatedWork W2356272953 @default.
• W2950559964 hasRelatedWork W2357345235 @default.
• W2950559964 hasRelatedWork W2944033593 @default.
• W2950559964 hasRelatedWork W9288866 @default.
• W2950559964 hasVolume "31" @default.
• W2950559964 isParatext "false" @default.
• W2950559964 isRetracted "false" @default.
• W2950559964 magId "2950559964" @default.
• W2950559964 workType "article" @default.